Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection

Table 2 Univariable and multivariable logistic regression for baseline factors associated with sustained virological response

	Univariable			Multivariablea
	OR	95%CI	P	OR	95%CI	P
Protease inhibitor, telaprevir	1.62	0.84-3.12	0.15	-	-	-
Age, yr	0.98	0.96-1.01	0.23	-	-	-
Gender, male	1.11	0.64-1.94	0.71	-	-	-
Race, white	3.12	1.41-6.90	< 0.01	5.92	2.34-14.96	< 0.01
Diabetes	0.43	0.21-0.87	0.02	-	-	-
Depression	1.58	0.83-3.02	0.17	-	-	-
BMI, kg/m2	0.98	0.93-1.04	0.52	-	-	-
IL28B, CC vs CT/TT	3.56	1.31-9.64	0.01	3.54	1.19-10.53	0.02
Treatment history, naïve/relapser	1.86	1.08-3.20	0.03	-	-	-
HCV viral load, log IU/mL	0.79	0.54-1.14	0.21	-	-	-
Sub-genotype, 1b (vs all other)	2.06	1.17-3.65	0.01	2.81	1.45-5.44	0.02
Hemoglobin, g/dL	1.03	0.86-1.23	0.78	-	-	-
AFP, ng/mL	0.95	0.92-0.98	< 0.01	-	-	-
Albumin, g/dL	2.56	1.33-4.92	< 0.01	-	-	-
AST, U/L	0.99	0.99-0.99	0.02	-	-	-
ALT, per U/L	1.00	0.99-1.01	0.61	-	-	-
Platelets, per × 104/µL	1.08	1.03-1.13	< 0.01	1.10	1.05-1.16	< 0.01
Creatinine, per mg/dL	0.8	0.42-1.53	0.50	-	-	-
Ferritin, per ng/mL	0.99	0.99-1.00	0.63	-	-	-
eGFR, per mL/min per 1.73 m2	1.00	0.99-1.02	0.65	-	-	-
APRI	0.84	0.70-1.02	0.08	-	-	-
FIB-4	0.91	0.83-0.99	0.02	-	-	-
APRI > 1.5	0.44	0.24-0.82	0.01	-	-	-
FIB-4 ≥ 3.25	0.39	0.22-0.68	< 0.01	-	-	-
Cirrhosis transient elastography/biopsy	0.5	0.29-0.87	0.01	-	-	-

^aModel includes platelets and no variable significantly correlated with platelets. BMI: Body mass index; HCV: Hepatitis C virus; AFP: Alpha-fetoprotein; AST: Aspartate transaminase; ALT: Alanine transaminase; eGFR: Estimated glomerular filtration rate; APRI: Aspartate transaminase to platelet ratio index.